Harborside


InMed Pharmaceuticals Inc.

INM


Canadian symbol: INM
US symbol: INM

Currency in USD

Valuation Measures4

Market Cap (intraday) 7.86M
Enterprise Value 2.84M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)4.65
Price/Book (mrq)0.72
Enterprise Value/Revenue 4.95
Enterprise Value/EBITDA -0.21

Trading Information

Stock Price History

Beta (5Y Monthly) 1.51
52-Week Change 3-87.83%
S&P500 52-Week Change 3-16.88%
52 Week High 359.25
52 Week Low 35.12
50-Day Moving Average 39.14
200-Day Moving Average 319.92

Share Statistics

Avg Vol (3 month) 3689.16k
Avg Vol (10 day) 33.76M
Shares Outstanding 51.41M
Implied Shares Outstanding 6N/A
Float 8899.27k
% Held by Insiders 10.56%
% Held by Institutions 14.83%
Shares Short (Aug 30, 2022) 4717
Short Ratio (Aug 30, 2022) 40.05
Short % of Float (Aug 30, 2022) 40.10%
Short % of Shares Outstanding (Aug 30, 2022) 40.10%
Shares Short (prior month Jul 28, 2022) 4702

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jul 05, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:25
Last Split Date 3Sept 06, 2022

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 29, 2022
Most Recent Quarter (mrq)Jun 29, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,247.60%

Management Effectiveness

Return on Assets (ttm)-75.28%
Return on Equity (ttm)-226.07%

Income Statement

Revenue (ttm)1.09M
Revenue Per Share (ttm)1.94
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)543.55k
EBITDA -13.41M
Net Income Avi to Common (ttm)-18.6M
Diluted EPS (ttm)-1.16
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)6.18M
Total Cash Per Share (mrq)6.8
Total Debt (mrq)793.77k
Total Debt/Equity (mrq)8.74
Current Ratio (mrq)2.89
Book Value Per Share (mrq)13.95

Cash Flow Statement

Operating Cash Flow (ttm)-15.58M
Levered Free Cash Flow (ttm)-8.95M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
INM
InMed Pharmaceuticals
3 days ago
INM
InMed Pharmaceuticals
3 months ago
INM
InMed Pharmaceuticals
3 months ago
INM
InMed Pharmaceuticals
3 months ago
INM
InMed Pharmaceuticals
4 months ago
INM
InMed Pharmaceuticals
4 months ago
INM
InMed Pharmaceuticals
4 months ago
INM
InMed Pharmaceuticals
4 months ago
INM
InMed Pharmaceuticals
6 months ago
INM
InMed Pharmaceuticals
7 months ago
INM
InMed Pharmaceuticals
7 months ago
INM
InMed Pharmaceuticals
7 months ago
INM
InMed Pharmaceuticals
8 months ago
INM
InMed Pharmaceuticals
8 months ago
INM
InMed Pharmaceuticals
9 months ago
INM
InMed Pharmaceuticals
9 months ago
INM
InMed Pharmaceuticals
10 months ago
INM
InMed Pharmaceuticals
10 months ago
INM
InMed Pharmaceuticals
10 months ago
INM
InMed Pharmaceuticals
10 months ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
1 year ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
2 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago
INM
InMed Pharmaceuticals
3 years ago

Currency in USD
Earnings EstimateCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
No. of Analysts1011
Avg. Estimate-5.50-25.5-8.75
Low Estimate-5.50-25.5-8.75
High Estimate-5.50-25.5-8.75
Year Ago EPS-10.25-6.25-38-25.5
Revenue EstimateCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
No. of Analysts1111
Avg. Estimate750k500k1.32M5M
Low Estimate750k500k1.32M5M
High Estimate750k500k1.32M5M
Year Ago SalesN/A250kN/A1.32M
Sales Growth (year/est)N/A100.00%N/A278.80%
Earnings History2021-06-292021-09-292021-12-302022-03-30
EPS Est.-8.5-8.75-5.87-6.25
EPS Actual-10.25-6.25-7.75-6.25
Difference-1.752.5-1.880
Surprise %-20.60%28.60%-32.00%0.00%
EPS TrendCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
Current Estimate-5.50-25.5-8.75
7 Days Ago-5.5-0.17-25.5-8.75
30 Days Ago-0.22-0.17-1-0.49
60 Days Ago-0.22-0.17-1-0.49
90 Days Ago-0.22-0.17-1-0.49
EPS RevisionsCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesINMIndustrySector(s)S&P 500
Current Qtr.46.30%N/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current Year32.90%N/AN/AN/A
Next Year65.70%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
0.56%% of Shares Held by All Insider
4.83%% of Shares Held by Institutions
4.86%% of Float Held by Institutions
18Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Armistice Capital, LLC38,245Jun 29, 20220.24%213,024
Renaissance Technologies, LLC1,988Jun 29, 20220.01%11,073
Two Sigma Advisers, LP1,931Jun 29, 20220.01%10,755
Advisor Group, Inc.47Jun 29, 20220.00%261
Citadel Advisors Llc519Jun 29, 20220.00%2,890
Creative Planning433Jun 29, 20220.00%2,411
Geode Capital Management, LLC556Jun 29, 20220.00%3,096
AllSquare Wealth Management LLC22Jun 29, 20220.00%122
National Bank of Canada/FI8Jun 29, 20220.00%44
Royal Bank of Canada10Jun 29, 20220.00%55

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Blackstone Alternative Multi-Strategy Fund48Jun 29, 20220.00%267
Fidelity NASDAQ Composite Index Fund556Jun 29, 20220.00%3,096
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by InMed Pharmaceuticals Inc.


InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 23, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. Conference Call & Webcast:Fri... Read More...
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

VANCOUVER, British Columbia, Sept. 19, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, Septemb... Read More...
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Sept. 13, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and... Read More...
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Sept. 09, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and ... Read More...
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

VANCOUVER, British Columbia, Sept. 08, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces an update on its research/development and commercial activities. Eric A. Adams, InMed CEO, states, “The Co... Read More...
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

VANCOUVER, British Columbia, Aug. 23, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces, pursuant to a directors’ resolution, InMed will be consolidating all of its issued and outstanding share capita... Read More...
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use of cannabinol for the treatment of epidermolysis bullosa VANCOUVER, British Columbia, July 25, 2022 ... Read More...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

VANCOUVER, British Columbia, July 12, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a research, development, manufacturing corporation specializing in the commercialization of rare cannabinoids, announces that, as previously disclosed pursuant to a Form 8-K filed with the Securities Exchange Commission on Ju... Read More...
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

VANCOUVER, British Columbia, June 14, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System ... Read More...
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoidBolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has been researched for a variety of potential benefits VANCOUVER, British Columbia, June 09, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the r... Read More...
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

VANCOUVER, British Columbia, June 06, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the closing of its previously announced registered direct offering and concurrent private placement with a singl... Read More...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel cannabinoid analogsAdvances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 13, 2022 -- InMed Pha... Read More...
InMed to Supply Rare Cannabinoids to Radicle Science's “Radicle Energy Study” to Assess the Health Effects of THCV

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on cannabinoids for consumers, brands and healthcare providers VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 05, 2022 -- InMed Pha... Read More...
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturin... Read More...
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing... Read More...
InMed to Participate in Upcoming Investor Conferences in April and May 2022

InMed to Participate in Upcoming Investor Conferences in April and May 2022

VANCOUVER, British Columbia, April 19, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announces that the Company's executive team will be participating in several investor events throughout April and May 2022. Ben... Read More...
InMed Announces Management Changes

InMed Announces Management Changes

VANCOUVER, British Columbia, March 17, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces that its Chief Financial Officer, Mr. Bruce Colwill, will be retiring and will be stepping down from his positi... Read More...
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica

InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica

VANCOUVER, British Columbia, Feb. 15, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a... Read More...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid laun... Read More...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

VANCOUVER, British Columbia, Feb. 10, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021... Read More...
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes cannabichromene (CBC)Strengthens leadership position in commercial scale production of high demand rare cannabinoids VANCOUVER, British Columbia, Jan.... Read More...
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

VANCOUVER, British Columbia, Jan. 05, 2022 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from President and CEO Eric A. Adams. Dear Shareholders, Colleagues, and Business Partners, I’d like to... Read More...
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma

InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma

VANCOUVER, British Columbia, Dec. 20, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific article entitled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potenti... Read More...
InMed Pharmaceuticals to Participate in Cowen's 4th Annual Cannabis Conference

InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

VANCOUVER, British Columbia, Nov. 23, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on... Read More...
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

Patent covers novel effects for neurodegenerative diseasesExpands InMed’s patent portfolio with incremental rare cannabinoid VANCOUVER, British Columbia, Nov. 03, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announ... Read More...
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a pri... Read More...
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

VANCOUVER, British Columbia, Sept. 30, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). Th... Read More...
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 24, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021. Conference Call & Webcast:Friday, September 24, 2021, at 8:00 AM Paci... Read More...
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

VANCOUVER, British Columbia, Sept. 17, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021. Conference Call & Webcast*:Friday, Septem... Read More...
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

Establishes leadership position in manufacturing and commercialization of rare cannabinoidsPositions InMed within large and growing consumer health and wellness cannabinoid marketsTransitions InMed into revenue generating company; acquires pipeline with numerous planned product launches VANCOUVER, British Columbia, Sept. 13, 2021 -- InMed... Read More...
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

VANCOUVER, British Columbia, Sept. 09, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that Eric. A. Adams, President and CEO of InMed will present at the H.C. Wainwright 23rd Annual Global Investment Conference which ... Read More...
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

VANCOUVER, British Columbia, Aug. 12, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that Eric. A. Adams, President and CEO, an... Read More...
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

VANCOUVER, British Columbia, July 02, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has closed the previously announce... Read More...
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

VANCOUVER, British Columbia, June 29, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has entered into a securities purc... Read More...
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

VANCOUVER, British Columbia, June 29, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has entered into a non-binding letter of... Read More...
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch production VANCOUVER, British Columbia, June 17, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage co... Read More...
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

VANCOUVER, British Columbia, June 09, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will present at... Read More...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 13, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2021 (“3Q21”)... Read More...
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 06, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), will report financial results on Thursday, May 13, 2021 for the third quart... Read More...
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

VANCOUVER, British Columbia, May 04, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will be ... Read More...
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks.Anticipated study on track to begin in 3Q 2021 VANCOUVER, British Columbia, April 28, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “... Read More...
InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

VANCOUVER, British Columbia, April 27, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that, based on the strong trading data on the Nasdaq, i... Read More...
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

VANCOUVER, British Columbia, April 26, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that its IntegraSyn™ cannabinoid manufacturing approach... Read More...
InMed Announces Closing of US$4.5 Million Private Placement

InMed Announces Closing of US$4.5 Million Private Placement

VANCOUVER, BC, Feb. 16, 2021 - InMed Pharmaceuticals Inc. ("InMed") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has closed the previously announced private placemen... Read More...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 11, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the second quarter of fiscal... Read More...
Coming Soon.

Delayed data (1h)


Share this page